INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Despite recent headwinds at present, the stock's outlook remains promising. Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it.

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion. But there's still ...

Eli Lilly's growth is impressive, driven by Mounjaro and Zepbound, but its current valuation is only justifiable with sustained high growth. Despite strong results and superior products ...

INDIANAPOLIS (WISH) — Employees of Indianapolis-based pharmaceutical giant Eli Lilly and Co. have logged ... of service is making a difference in Indiana. Kent Kramer, president and CEO of ...

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. The Big Pharma has penned a deal to acquire SiteOne Therapeutics, primarily for a non-opioid pain asset ready to ...

INDIANAPOLIS — Former Eli Lilly and Co. CEOs John Lechleiter and Randall Tobias, and their wives Deborah and Sarah, have partnered on a $20 million gift to establish the Tobias-Lechleiter Institute ...

Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup with a lead program that addresses the same target as a Vertex Pharmaceuticals product whose ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...